Why does LRMR lag the market?
Up 8% over three years while the S&P 500 rose 80%.
- It filed a prospectus for an offering of shares of $100.0M on Feb 26, 2026.
−3Long-term trend
The timeline, for Pro members.
Larimar Therapeutics (LRMR) stock
$2.69
Quality Score
-6
In its industry
#226of 281
Checks firing
3of 14
From 52-week high
-58.1%
Follow LRMR's trial news. Pro members can get an alert when Larimar Therapeutics files news, and see its trials, share raises, and its CEO's filings.
Get an alert when LRMR files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Next2H 2026“…for Broad FA Population Rolling BLA submission initiated First module submittedCompletion expected 2H 2026…”
Key facts on LRMR
| Holding it back | 63.0% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
1 more reason behind LRMR's -6, free with an account →3 more reasons behind LRMR's -6, for Pro members.
LRMR in the news
ReportLast night: the results are out. Past reports ›
LRMR catalysts
Coming up
After its last 4 reports it closed +2.1% on average, higher 3 of 4 times.
What's next for LRMR, and how long its cash lasts
Next step the company has named
2H 2026“…Modifying Therapy for Broad FA Population Rolling BLA submission initiated First module submittedCompletion expected 2H 2026 Dosing of first patient in global Phase 3 trial expected Q3…”
Cash runway
$156M in cash
Dilution on the horizon
- Shelf registration (S-3, filed May 9, 2024)
- At-the-market share sales program (S-3, filed May 9, 2024)
Insiders
Director Thomas Edward Hamilton bought 50,000 shares on Jul 6. 4 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
How LRMR ranks in Biotech
LRMR is #226 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 226 |
When does LRMR report earnings, and what happens after?
Expected to report Wed Nov 11, before the open (tomorrow).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Close after the report, last 3
-5.1%+3.3%+6.3%
May 14Aug 4Nov 9
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -1.2% | +6.3% | not yet |
| Aug 4, 2026 | 0.0% | +3.3% | +0.8% |
| May 14, 2026 | +1.0% | -5.1% | -13.9% |
LRMR has 3 of 14 chart checks firing
The other 10 checks on LRMR, and all 14 on every stock.Get in free →
LRMR RSI today: 52.0, below its 50-day and 200-day averages
RSI 52.0, MACD above signal, below both averages. Not scored.
The deep dive on LRMR
- What it does and how it makes moneySEC filing · Mar 5, 2020
- Where it standsBalance sheet of Jun 30, 2026, filed Aug 4, 2026
- What changed in its filingsSEC filing · May 7, 2020SEC filing · Mar 5, 2020
- Who holds and trades it
LRMR insider trades
One insider bought $167K across 1 filing in the last 6 months. No open-market sales on record. The newest:
BuyThomas Edward Hamilton$167K
LRMR's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold LRMR?
In ETFs: LRMR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
What Larimar Therapeutics says it competes with
“The biopharmaceuticals industry is highly competitive.”
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn LRMR's score around: 7 things
- 7 more filings explained, a plain line each
- 4 more things pulling LRMR's score down
BreakawayJul 8Thomas Edward Hamilton bought LRMR
Straight AnswersStraight Answers
What does LRMR's Quality Score say?
LRMR scores -6 today, which Breakaway calls Poor. It is #226 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 8% over three years while the S&P 500 rose 80%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is LRMR's Quality Score?
LRMR scores -6 today, which Breakaway calls Poor (below zero). That is #226 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LRMR's -6.
Are insiders buying LRMR?
One insider bought $167K across 1 filing in the last 6 months. No open-market sales on record. The newest is Thomas Edward Hamilton, Director, who bought $167K on Jul 6.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.